Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Beom-Jun Kim  (Kim BJ) 8 Articles
Calcium & bone metabolism
Beyond Bone: Embracing Osteosarcopenia for Comprehensive Fracture Prevention
Beom-Jun Kim
Endocrinol Metab. 2024;39(3):531-533.   Published online May 16, 2024
DOI: https://doi.org/10.3803/EnM.2024.2002
  • 796 View
  • 37 Download
PDFPubReader   ePub   
Close layer
Calcium & bone metabolism
Higher Plasma Stromal Cell-Derived Factor 1 Is Associated with Lower Risk for Sarcopenia in Older Asian Adults
Sunghwan Ji, Kyunggon Kim, So Jeong Park, Jin Young Lee, Hee-Won Jung, Hyun Ju Yoo, Il-Young Jang, Eunju Lee, Ji Yeon Baek, Beom-Jun Kim
Endocrinol Metab. 2023;38(6):701-708.   Published online October 18, 2023
DOI: https://doi.org/10.3803/EnM.2023.1783
  • 2,074 View
  • 83 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Despite the protective effects of stromal cell-derived factor 1 (SDF-1) in stimulating muscle regeneration shown in experimental research, there is a lack of clinical studies linking circulating SDF-1 concentrations with muscle phenotypes. In order to elucidate the role of SDF-1 as a potential biomarker reflecting human muscle health, we investigated the association of plasma SDF-1 levels with sarcopenia in older adults.
Methods
This cross-sectional study included 97 community-dwelling participants who underwent a comprehensive geriatric assessment at a tertiary hospital in South Korea. Sarcopenia was defined by specific cutoff values applicable to the Asian population, whereas plasma SDF-1 levels were determined using an enzyme immunoassay.
Results
After accounting for sex, age, and body mass index, participants with sarcopenia and low muscle mass exhibited plasma SDF-1 levels that were 21.8% and 18.3% lower than those without these conditions, respectively (P=0.008 and P=0.009, respectively). Consistently, higher plasma SDF-1 levels exhibited a significant correlation with higher skeletal muscle mass index (SMI) and gait speed (both P=0.043), and the risk of sarcopenia and low muscle mass decreased by 58% and 55% per standard deviation increase in plasma SDF-1 levels, respectively (P=0.045 and P=0.030, respectively). Furthermore, participants in the highest SDF-1 tertile exhibited significantly higher SMI compared to those in the lowest tertile (P=0.012).
Conclusion
These findings clinically corroborate earlier experimental discoveries highlighting the muscle anabolic effects of SDF- 1 and support the potential role of circulating SDF-1 as a biomarker reflecting human muscle health in older adults.
Close layer
Calcium & Bone Metabolism
Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia
Seong Hee Ahn, Hee-Won Jung, Eunju Lee, Ji Yeon Baek, Il-Young Jang, So Jeong Park, Jin Young Lee, Eunah Choi, Yun Sun Lee, Seongbin Hong, Beom-Jun Kim
Endocrinol Metab. 2022;37(3):487-496.   Published online May 27, 2022
DOI: https://doi.org/10.3803/EnM.2022.1428
  • 3,513 View
  • 150 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Although muscles and bones interact with each other through various secretory factors, the role of sclerostin, an osteocyte-secreted factor, on muscle metabolism has not been well studied. We investigated the levels of serum sclerostin in Korean older adults with sarcopenia.
Methods
Blood samples were collected from 129 participants who underwent evaluation of muscle mass and function in an outpatient geriatric clinic of a teaching hospital. Sarcopenia and related parameters were determined using cutoff values for the Asian population. Serum sclerostin levels were measured using an enzyme-linked immunosorbent assay.
Results
The mean age of the participants was 69.6 years, and 20 participants (15.5%) were classified as having sarcopenia. After adjusting for age, sex, and body mass index, serum sclerostin levels were significantly lower in participants with sarcopenia, low muscle mass, or weak muscle strength (P=0.003 to 0.045). Serum sclerostin levels were positively associated with skeletal muscle index and grip strength after adjusting for confounders (P=0.001 and P=0.003), whereas sarcopenic phenotype score showed a negative association (P=0.006). These increases in muscle mass and strength were also dose dependent as serum sclerostin levels increased (P for trends=0.003 and P for trends=0.015). Higher serum sclerostin levels were associated with lower odds ratio (ORs) for sarcopenia, low muscle mass, and weak muscle strength after adjusting for confounders (OR, 0.27 to 0.50; P<0.001 to 0.025).
Conclusion
Higher serum sclerostin levels were associated with a lower risk of sarcopenia, low muscle mass, and weak muscle strength in Korean older adults.

Citations

Citations to this article as recorded by  
  • Mechanism and physical activities in bone-skeletal muscle crosstalk
    Zhonghan Zhao, Kai Yan, Qiao Guan, Qiang Guo, Can Zhao
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Musculoskeletal disorders and coronary artery disease —promising molecular markers: literature review
    Viktoria N. Karetnikova, Anastasiya G. Neeshpapa, Evgenia I. Carpova, Olga L. Barbarash
    CardioSomatics.2024; 15(1): 55.     CrossRef
  • Differences in Type 2 Fiber Composition in the Vastus Lateralis and Gluteus Maximus of Patients with Hip Fractures
    Jingwen Tian, Minchul Song, Kyu Jeong Cho, Ho Yeop Lee, Sang Hyeon Ju, Jung Ryul Lim, Ha Thi Nga, Thi Linh Nguyen, Ji Sun Moon, Hyo Ju Jang, Jung-Mo Hwang, Hyon-Seung Yi
    Endocrinology and Metabolism.2024; 39(3): 521.     CrossRef
  • Determinants of bone mass in older adults with normal- and overweight derived from the crosstalk with muscle and adipose tissue
    Carina O. Walowski, Catrin Herpich, Janna Enderle, Wiebke Braun, Marcus Both, Mario Hasler, Manfred J. Müller, Kristina Norman, Anja Bosy-Westphal
    Scientific Reports.2023;[Epub]     CrossRef
  • Role of the Osteocyte in Musculoskeletal Disease
    Anika Shimonty, Lynda F. Bonewald, Fabrizio Pin
    Current Osteoporosis Reports.2023; 21(3): 303.     CrossRef
  • The role of sclerostin in lipid and glucose metabolism disorders
    Hewen Jiang, Dijie Li, Ying Han, Nanxi Li, Xiaohui Tao, Jin Liu, Zongkang Zhang, Yuanyuan Yu, Luyao Wang, Sifan Yu, Ning Zhang, Huan Xiao, Xin Yang, Yihao Zhang, Ge Zhang, Bao-Ting Zhang
    Biochemical Pharmacology.2023; 215: 115694.     CrossRef
  • Cytokines and exosomal miRNAs in skeletal muscle–adipose crosstalk
    Liu Guo, Menchus Quan, Weijun Pang, Yulong Yin, Fengna Li
    Trends in Endocrinology & Metabolism.2023; 34(10): 666.     CrossRef
  • Sclerostin: clinical insights in muscle–bone crosstalk
    Antimo Moretti, Giovanni Iolascon
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Anti-sclerostin antibodies: a new frontier in fragility fractures treatment
    Giovanni Iolascon, Sara Liguori, Marco Paoletta, Giuseppe Toro, Antimo Moretti
    Therapeutic Advances in Musculoskeletal Disease.2023;[Epub]     CrossRef
  • Sclerostin as a Putative Myokine in Sarcopenia
    Hyon-Seung Yi
    Endocrinology and Metabolism.2022; 37(3): 430.     CrossRef
  • Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise
    Giulia Minniti, Letícia Maria Pescinini-Salzedas, Guilherme Almeida dos Santos Minniti, Lucas Fornari Laurindo, Sandra Maria Barbalho, Renata Vargas Sinatora, Lance Alan Sloan, Rafael Santos de Argollo Haber, Adriano Cressoni Araújo, Karina Quesada, Jesse
    International Journal of Molecular Sciences.2022; 23(21): 13452.     CrossRef
Close layer
Adrenal Gland
Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim
Endocrinol Metab. 2021;36(4):865-874.   Published online July 30, 2021
DOI: https://doi.org/10.3803/EnM.2021.1108
  • 4,655 View
  • 114 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Despite clinical evidence indicating poor muscle health in subjects with primary aldosteronism (PA), it is still unclear whether the role of aldosterone in muscle metabolism is direct or mediated indirectly via factors, such as electrolyte imbalance or impaired glucose uptake. As one approach to clarify this issue, we investigated the effect of aldosterone on in vitro myogenesis and the potential mechanism explaining it.
Methods
Myogenesis was induced in mouse C2C12 myoblasts with 2% horse serum. Immunofluorescence, quantitative reversetranscription polymerase chain reaction, Western blot, viability, and migration analyses were performed for experimental research.
Results
Recombinant aldosterone treatment suppressed muscle differentiation from mouse C2C12 myoblasts in a dose-dependent manner, and consistently reduced the expression of myogenic differentiation markers. Furthermore, aldosterone significantly increased intracellular reactive oxygen species (ROS) levels in myotubes, and treatment with N-acetyl cysteine, a potent biological thiol antioxidant, reversed the decrease of myotube area, myotube area per myotube, nucleus number per myotube, and fusion index due to aldosterone through decreasing oxidative stress. A binding enzyme-linked immunosorbent assay confirmed that mineralocorticoid receptor (MR) interacted with aldosterone in C2C12 myoblasts, while eplerenone, an MR inhibitor, blocked aldosterone-stimulated intracellular ROS generation during myogenesis and markedly attenuated the suppression of in vitro myogenesis by aldosterone.
Conclusion
These findings support the hypothesis that hypersecretion of aldosterone, like PA, directly contributes to muscular deterioration and suggest that antioxidants and/or MR antagonists could be effective therapeutic options to reduce the risk of sarcopenia in these patients.

Citations

Citations to this article as recorded by  
  • Molecular mechanisms underlying sarcopenia in heart failure
    Cody A. Rutledge
    The Journal of Cardiovascular Aging.2024;[Epub]     CrossRef
  • Role of glucocorticoid and mineralocorticoid receptors in rainbow trout (Oncorhynchus mykiss) skeletal muscle: A transcriptomic perspective of cortisol action
    Jorge E. Aedo, Rodrigo Zuloaga, Daniela Aravena-Canales, Alfredo Molina, Juan Antonio Valdés
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Effect of 11-Deoxycorticosterone in the Transcriptomic Response to Stress in Rainbow Trout Skeletal Muscle
    Rodrigo Zuloaga, Daniela Aravena-Canales, Jorge Eduardo Aedo, Cesar Osorio-Fuentealba, Alfredo Molina, Juan Antonio Valdés
    Genes.2023; 14(2): 512.     CrossRef
  • Heart Failure Medication and Muscle Wasting
    Yasuhiro Izumiya
    Circulation Journal.2023; 88(1): 20.     CrossRef
  • 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
    Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung
    Endocrinology and Metabolism.2023; 38(6): 597.     CrossRef
  • Higher Plasma Stromal Cell-Derived Factor 1 Is Associated with Lower Risk for Sarcopenia in Older Asian Adults
    Sunghwan Ji, Kyunggon Kim, So Jeong Park, Jin Young Lee, Hee-Won Jung, Hyun Ju Yoo, Il-Young Jang, Eunju Lee, Ji Yeon Baek, Beom-Jun Kim
    Endocrinology and Metabolism.2023; 38(6): 701.     CrossRef
  • The Role of Aldosterone in OSA and OSA-Related Hypertension
    Yi Wang, Chuan Xiang Li, Ying Ni Lin, Li Yue Zhang, Shi Qi Li, Liu Zhang, Ya Ru Yan, Fang Ying Lu, Ning Li, Qing Yun Li
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
Close layer
Endocrine Research
Effect of CCL11 on In Vitro Myogenesis and Its Clinical Relevance for Sarcopenia in Older Adults
Da Ae Kim, So Jeong Park, Jin Young Lee, Jeoung Hee Kim, Seungjoo Lee, Eunju Lee, Il-Young Jang, Hee-Won Jung, Jin Hoon Park, Beom-Jun Kim
Endocrinol Metab. 2021;36(2):455-465.   Published online April 14, 2021
DOI: https://doi.org/10.3803/EnM.2020.942
  • 5,540 View
  • 150 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The C-C motif chemokine ligand 11 (CCL11) has been receiving attention as a potential pro-aging factor. Accordingly, it may be involved in muscle metabolism and sarcopenia, a key component of aging phenotypes. To clarify this potential, we investigated the effects of CCL11 on in vitro muscle biology and its clinical relevance for sarcopenia parameters in older adults.
Methods
Myogenesis was induced in mouse C2C12 myoblasts with 2% horse serum. Human blood samples were collected from 79 participants who underwent a functional assessment. Thereafter, CCL11 level was measured using a quantikine ELISA kit. Sarcopenia was defined using the Asian-specific guideline.
Results
Recombinant CCL11 treatment significantly stimulated myogenesis in a dose-dependent manner, and consistently increased the expression of myogenic differentiation markers. Among the C-C chemokine receptors (CCRs), CCR5, not CCR2 and CCR3, was predominantly expressed in muscle cells. Further, the CCR5 inhibitor blocked recombinant CCL11-stimulated myogenesis. In a clinical study, serum CCL11 level was not significantly different according to the status of sarcopenia, low muscle mass, weak muscle strength, and poor physical performance, and was not associated with skeletal muscle index, grip strength, short physical performance battery score, gait speed, and time to complete 5 chair stands, after adjusting for sex, age, and body mass index.
Conclusion
Contrary to expectations, CCL11 exerted beneficial effects on muscle metabolism at least in vitro system. However, its impact on human muscle health was not evident, suggesting that circulating CCL11 may not be a useful biomarker for sarcopenia risk assessment in older adults.

Citations

Citations to this article as recorded by  
  • Mapping the causal associations of cytokines with sarcopenia and aging traits: Evidence from bidirectional Mendelian randomization
    Mingchong Liu, Xiao Fu, Daqian Yu, Meng Li, Yutao Pan, Chensong Yang, Guixin Sun
    Journal of Cachexia, Sarcopenia and Muscle.2024; 15(3): 1121.     CrossRef
  • C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease
    Zhiwen Fan, Xinyue Sun, Xuelian Chen, Huimin Liu, Xiulian Miao, Yan Guo, Yong Xu, Jie Li, Xiaoping Zou, Zilong Li
    JHEP Reports.2023; : 100754.     CrossRef
  • C–C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease
    Zhiwen Fan, Xinyue Sun, Xuelian Chen, Huimin Liu, Xiulian Miao, Yan Guo, Yong Xu, Jie Li, Xiaoping Zou, Zilong Li
    JHEP Reports.2023; 5(9): 100805.     CrossRef
  • Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity
    Jin-Young Lee, Da-Ae Kim, Eun-Young Kim, Eun-Ju Chang, So-Jeong Park, Beom-Jun Kim
    International Journal of Molecular Sciences.2021; 22(9): 4717.     CrossRef
  • Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
    Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim
    Endocrinology and Metabolism.2021; 36(4): 865.     CrossRef
Close layer
Bone Metabolism
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
Endocrinol Metab. 2020;35(1):55-63.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.55
  • 5,181 View
  • 119 Download
  • 16 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   ePub   

Osteoporotic fracture (OF) is associated with high disability and morbidity rates. The burden of OF may be reduced by early identification of subjects who are vulnerable to fracture. Although the current fracture risk assessment model includes clinical risk factors (CRFs) and bone mineral density (BMD), its overall ability to identify individuals at high risk for fracture remains suboptimal. Efforts have therefore been made to identify potential biomarkers that can predict the risk of OF, independent of or combined with CRFs and BMD. This review highlights the emerging biomarkers of bone metabolism, including sphongosine-1-phosphate, leucine-rich repeat-containing 17, macrophage migration inhibitory factor, sclerostin, receptor activator of nuclear factor-κB ligand, and periostin, and the importance of biomarker risk score, generated by combining these markers, in enhancing the accuracy of fracture prediction.

Citations

Citations to this article as recorded by  
  • Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice
    Weihang Gao, Jiao Jiao Li, Jingyu Shi, Hongbing Lan, Yuanyuan Guo, Dehao Fu
    Journal of Nanobiotechnology.2024;[Epub]     CrossRef
  • Changes in bone turnover markers 6–12 months after bariatric surgery
    Per G. Farup
    Scientific Reports.2024;[Epub]     CrossRef
  • The administration of bovine hydroxyapatite-alendronate implant accelerates bone defect healing in an osteoporotic rat
    Toetik Aryani, Aniek Setiya Budiatin, Samirah, Aulia Maulidina, Aulia Intan Firdaus, Maria Apriliani Gani, Khoirotin Nisak, Junaidi Khotib, Alvi Jauharotus Syukriya
    Technology and Health Care.2023; 31(5): 1747.     CrossRef
  • Impact of Intravenous Iron Substitution on Serum Phosphate Levels and Bone Turnover Markers—An Open-Label Pilot Study
    Alexandra Struppe, Jakob E. Schanda, Andreas Baierl, Paul Watzl, Christian Muschitz
    Nutrients.2023; 15(12): 2693.     CrossRef
  • Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
    Vladimir Gerov, Daniela Gerova, Ilina Micheva, Miglena Nikolova, Galya Mihaylova, Bistra Galunska
    Journal of Clinical Medicine.2023; 12(13): 4440.     CrossRef
  • Impact of vitamin D supplementation on markers of bone turnover: Systematic review and meta‐analysis of randomised controlled trials
    Mohammad Hassan Sohouli, Sicong Wang, Faisal Almuqayyid, Mariana Papini Gabiatti, Fateme Mozaffari, Zahra Mohamadian, Nazanin Koushki, Kamar Allayl Alras, Abdullah M. AlHossan, Saud K. Albatati, Aya Alfardous Alazm, Saeed Baradwan, Mihnea‐Alexandru Găman,
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Night shift work and serum markers of bone turnover in male shift workers
    Margherita Martelli, Gianmaria Salvio, Raffaella Lazzarini, Marijana Milinkovic, Alessandro Ciarloni, Giancarlo Balercia, Lory Santarelli, Massimo Bracci
    Chronobiology International.2023; 40(9): 1270.     CrossRef
  • Circulating sRANKL, Periostin, and Osteopontin as Biomarkers for the Assessment of Activated Osteoclastogenesis in Myeloma Related Bone Disease
    Vladimir Gerov, Daniela Gerova, Ilina Micheva, Miglena Nikolova, Milena Pasheva, Neshe Nazifova, Bistra Galunska
    Cancers.2023; 15(23): 5562.     CrossRef
  • Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide
    Subhashis Pal, Shivani Sharma, Konica Porwal, Mohammed Riyazuddin, Chirag Kulkarni, Sourav Chattopadhyay, Sabyasachi Sanyal, Jiaur R. Gayen, Naibedya Chattopadhyay
    Calcified Tissue International.2022; 111(2): 196.     CrossRef
  • Serum sclerostin levels in osteoporotic fracture patients
    Erwin A. Gorter, Casper R. Reinders, Pieta Krijnen, Natasha M. Appelman-Dijkstra, Inger B. Schipper
    European Journal of Trauma and Emergency Surgery.2022; 48(6): 4857.     CrossRef
  • Elevated gamma-glutamyl transpeptidase level is associated with an increased risk of hip fracture in postmenopausal women
    Kyoung Jin Kim, Namki Hong, Min Heui Yu, Seunghyun Lee, Sungjae Shin, Sin Gon Kim, Yumie Rhee
    Scientific Reports.2022;[Epub]     CrossRef
  • Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
    Alice Wang, Nishi Karunasinghe, Lindsay D. Plank, Shuotun Zhu, Sue Osborne, Charis Brown, Karen Bishop, Tiffany Schwass, Sofian Tijono, Michael Holmes, Jonathan Masters, Roger Huang, Christine Keven, Lynnette R. Ferguson, Ross Lawrenson
    Scientific Reports.2021;[Epub]     CrossRef
  • Update on Glucocorticoid Induced Osteoporosis
    Soo-Kyung Cho, Yoon-Kyoung Sung
    Endocrinology and Metabolism.2021; 36(3): 536.     CrossRef
  • Nobiletin promotes osteogenic differentiation of human osteoblastic cell line (MG-63) through activating the BMP-2/RUNX-2 signaling pathway
    Ying Pang, Lili Liu, Hong Mu, Vishnu Priya Veeraraghavan
    Saudi Journal of Biological Sciences.2021; 28(9): 4916.     CrossRef
Close layer
Adrenal gland
Bone Health in Adrenal Disorders
Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
Endocrinol Metab. 2018;33(1):1-8.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.1
  • 5,425 View
  • 54 Download
  • 14 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   ePub   

Secondary osteoporosis resulting from specific clinical disorders may be potentially reversible, and thus continuous efforts to find and adequately treat the secondary causes of skeletal fragility are critical to ameliorate fracture risk and to avoid unnecessary treatment with anti-osteoporotic drugs. Among the hyperfunctional adrenal masses, Cushing's syndrome, pheochromocytoma, and primary aldosteronism are receiving particularly great attention due to their high morbidity and mortality mainly by increasing cardiovascular risk. Interestingly, there is accumulating experimental and clinical evidence that adrenal hormones may have direct detrimental effects on bone metabolism as well. Thus, the present review discusses the possibility of adrenal disorders, especially focusing on pheochromocytoma and primary aldosteronism, as secondary causes of osteoporosis.

Citations

Citations to this article as recorded by  
  • High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
    Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
    Clinical Gastroenterology and Hepatology.2022; 20(5): e1022.     CrossRef
  • Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
    Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
    Cancers.2022; 14(8): 1967.     CrossRef
  • Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis
    Anning Wang, Yuhan Wang, Hongzhou Liu, Xiaodong Hu, Jiefei Li, Huaijin Xu, Zhimei Nie, Lingjing Zhang, Zhaohui Lyu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion
    Mara Carsote
    Diagnostics.2022; 12(11): 2772.     CrossRef
  • Elemental profiling of adrenal adenomas in solid tissue and blood samples by ICP-MS and ICP-OES
    Jovana Jagodić, Branislav Rovčanin, Đurđa Krstić, Ivan Paunović, Vladan Živaljević, Dragan Manojlović, Aleksandar Stojsavljević
    Microchemical Journal.2021; 165: 106194.     CrossRef
  • Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
    Jin Young Lee, Da Ae Kim, Eunah Choi, Yun Sun Lee, So Jeong Park, Beom-Jun Kim
    Endocrinology and Metabolism.2021; 36(4): 865.     CrossRef
  • Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service
    Jung Hee Kim, Hyemi Moon, Junghyun Noh, Juneyoung Lee, Sin Gon Kim
    Endocrinology and Metabolism.2020; 35(1): 157.     CrossRef
  • Pheochromocytoma and paraganglioma: An emerging cause of secondary osteoporosis
    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Tazuru Fukumoto, Yayoi Matsuda, Hiromi Nagata, Masatoshi Ogata, Hisaya Kawate, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa
    Bone.2020; 133: 115221.     CrossRef
  • Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
    Christian Adolf, Leah T. Braun, Carmina T. Fuss, Stefanie Hahner, Heike Künzel, Laura Handgriff, Lisa Sturm, Daniel A. Heinrich, Holger Schneider, Martin Bidlingmaier, Martin Reincke
    Endocrine.2020; 69(3): 625.     CrossRef
  • Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis
    Shaomin Shi, Chunyan Lu, Haoming Tian, Yan Ren, Tao Chen
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Understanding and managing secondary osteoporosis
    Luciano Colangelo, Federica Biamonte, Jessica Pepe, Cristiana Cipriani, Salvatore Minisola
    Expert Review of Endocrinology & Metabolism.2019; 14(2): 111.     CrossRef
  • Evaluation of bone health in patients with adrenal tumors
    Shobana Athimulam, Irina Bancos
    Current Opinion in Endocrinology, Diabetes & Obesity.2019; 26(3): 125.     CrossRef
Close layer
Clinical Study
The Association of Higher Plasma Macrophage Migration Inhibitory Factor Levels with Lower Bone Mineral Density and Higher Bone Turnover Rate in Postmenopausal Women
Hyeonmok Kim, Seong Hee Ahn, Chaeho Shin, Seung Hun Lee, Beom-Jun Kim, Jung-Min Koh
Endocrinol Metab. 2016;31(3):454-461.   Published online July 26, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.454
  • 4,027 View
  • 44 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Despite evidence from animal and clinical studies showing the detrimental effects of macrophage migration inhibitory factor (MIF) on bone metabolism, there are no clinical studies relating circulating MIF levels to osteoporosis-related phenotypes. This cross-sectional study investigated the association of plasma MIF with bone mineral density (BMD), bone turnover markers (BTMs), and prevalence of osteoporosis in postmenopausal Korean women.

Methods

A total of 246 women not taking any medications or diagnosed with any diseases that could affect bone metabolism were enrolled. BMD values at the lumbar spine, femoral neck, and total femur, and blood levels of MIF and BTMs were measured in all subjects. Osteoporosis was defined by World Health Organization criteria.

Results

Before and after adjustment for confounding variables, higher MIF levels were significantly associated with lower BMD values at all measured sites and higher levels of all BTMs. All BMD values and BTMs significantly changed in a dose-dependent fashion across increasing MIF quartile. When participants were divided into two groups according to osteoporosis status, postmenopausal women with osteoporosis demonstrated 24.2% higher plasma MIF levels than those without osteoporosis (P=0.041). The odds ratio per each standard deviation increment of MIF levels for prevalent osteoporosis was 1.32 (95% confidence interval, 1.01 to 1.73).

Conclusion

This study provides the first epidemiological evidence that higher plasma MIF may be associated with higher risk of osteoporosis resulting from lower bone mass and higher bone turnover rate, and thus it could be a potential biomarker of poor bone health outcomes in postmenopausal women.

Citations

Citations to this article as recorded by  
  • The role of MIF in periodontitis: A potential pathogenic driver, biomarker, and therapeutic target
    Tongfeng Fang, Liu Liu, Dongzhe Song, Dingming Huang
    Oral Diseases.2024; 30(3): 921.     CrossRef
  • Variation of Bone Turnover Markers in Childhood and Adolescence
    Yiduo Zhang, Jing Zhang, Xiaocui Huang, Xingnan Yu, Ye Li, Fan Yu, Wenjie Zhou, Ziqing Li
    International Journal of Clinical Practice.2023; 2023: 1.     CrossRef
  • Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
    Elena Schwendich, Laura Salinas Tejedor, Gernot Schmitz, Markus Rickert, Jürgen Steinmeyer, Stefan Rehart, Styliani Tsiami, Jürgen Braun, Xenofon Baraliakos, Jörg Reinders, Elena Neumann, Ulf Müller-Ladner, Silvia Capellino
    Cells.2022; 11(10): 1609.     CrossRef
  • Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes
    Elisabeth Gjefsen, Kristina Gervin, Guro Goll, Lars Christian Haugli Bråten, Monica Wigemyr, Hans Christian D Aass, Maria Dehli Vigeland, Elina Schistad, Linda Margareth Pedersen, Are Hugo Pripp, Kjersti Storheim, Kaja Kristine Selmer, John Anker Zwart
    RMD Open.2021; 7(2): e001726.     CrossRef
  • Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
    Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
    Endocrinology and Metabolism.2020; 35(1): 55.     CrossRef
  • Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis
    Mohammed Howait, Abdullah Albassam, Chiaki Yamada, Hajime Sasaki, Laila Bahammam, Mariane Maffei Azuma, Luciano Tavares Angelo Cintra, Abhay R. Satoskar, Satoru Yamada, Robert White, Toshihisa Kawai, Alexandru Movila
    The Journal of Immunology.2019; 202(7): 2035.     CrossRef
  • Preventive Effects of Low Parathyroid Hormone Levels on Hip Fracture in Patients with Vitamin D Deficiency
    Seong-Eun Byun, Soonchul Lee, Ji Wan Kim, Yong-Chan Ha, Chul-Ho Kim, Cheungsoo Ha, Keun Jung Ryu, Jung-Min Koh, Hyung Kyung Kim, Jae Suk Chang
    Journal of Bone Metabolism.2019; 26(2): 89.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • New Biological Markers of Bone Metabolism in Osteoporosis Treatment
    Sun Wook Cho
    Endocrinology and Metabolism.2016; 31(3): 400.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism